- Low pretreatment serum albumin predicts poorer outcomes and can be used for risk stratification in nasopharyngeal carcinoma (NPC).
Why this matters
- Serum albumin is regularly used as a nutritional index in clinical practice.
- Pretreatment levels have been linked to prognosis in hepatocellular carcinoma, colorectal cancer, and lung cancer.
- Its value in NPC is controversial due to a paucity of data.
- Low pretreatment serum albumin (cutoffs used varied between 35 and 47 g/L) predicted shorter OS (HR, 1.32; P<.001 and distant metastasis-free survival hr>
- In subgroup analysis, low albumin predicted poorer OS and DMFS in patients with nonmetastatic NPC (HR, 1.40; P<.001 and hr respectively but not in patients with metastatic npc>
- Meta-analysis of 10 retrospective studies involving 7339 patients with NPC.
- Funding: Science and Technology Fund of the Tianjin Health Bureau.
- Heterogeneity between included studies.
- Only retrospective studies included.